{
  "id": "antibody-drug-conjugate",
  "title": "Antibody–Drug Conjugate",
  "lang": "en",
  "source_lang": "en",
  "summary": "A targeted therapeutic that chemically links an antibody to a drug, usually to deliver a cytotoxic payload to cancer cells.",
  "category": "health",
  "subcategory": "drugs",
  "type": "concept",
  "aliases": [
    "ADC",
    "antibody-drug conjugate"
  ],
  "generated_at": "2026-10-22",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/antibody-drug-conjugate/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/antibody-drug-conjugate/",
      "json": "https://aiwiki.page/zh/antibody-drug-conjugate.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "An antibody–drug conjugate (ADC) is a therapeutic substance in which an antibody, usually a monoclonal antibody, is chemically joined to a drug through a linker. In oncology, the antibody recognizes a target antigen on cells, while the attached drug, called the payload, supplies cytotoxic activity. Following target binding, many ADCs enter cells and release active drug through intracellular processing. This design combines molecular recognition with drug delivery rather than simply administering an antibody and a drug together. (cancer.gov)\n\nADCs are important in the treatment of selected blood cancers and solid tumors, including forms of breast cancer. Their properties depend on the interaction of antibody, linker, payload, and conjugation chemistry, as well as the biological characteristics of the tumor. Targeting does not eliminate injury to healthy tissue: systemic exposure to active drug, treatment-related toxicity, and resistance remain important limitations. Understanding ADCs therefore requires consideration of their molecular engineering, cellular action, manufacturing, clinical evidence, and safety as an integrated therapeutic system. (cancer.gov)"
    },
    {
      "heading": "Definition and Therapeutic Boundaries",
      "text": "An antibody–drug conjugate (ADC) is a therapeutic construct with three core components: an antibody or antibody fragment, a chemical linker, and a drug payload. In the oncology ADCs considered here, the payload is a cytotoxic small molecule chemically attached to the antibody through covalent bonds. The antibody provides recognition of a target antigen, the linker connects the components, and the payload supplies cell-killing activity. These roles are complementary rather than interchangeable: the antibody is not itself the attached chemotherapy drug, and the linker is part of the delivery system rather than a separately administered treatment. (fda.gov)\n\nThe intact conjugate must be distinguished from its unconjugated constituents. “Conjugated antibody” denotes antibody carrying attached payload, whereas unconjugated antibody carries none; unconjugated payload is drug no longer attached to the antibody. Processing of the conjugate can also produce drug-containing breakdown products. Consequently, the administered ADC and the substances subsequently present in the body are not a single chemically invariant entity. Their biological activities and disposition can differ, so measuring antibody alone does not necessarily establish how much antibody-associated drug remains. This distinction underlies the separate assessment of the conjugate and relevant constituents in clinical pharmacology. (fda.gov)\n\nChemical attachment separates an ADC from both an unconjugated therapeutic monoclonal antibody and a regimen in which an antibody and chemotherapy are administered separately. Trastuzumab emtansine, also called T-DM1, illustrates the distinction: it incorporates the HER2-binding antibody trastuzumab, an MCC linker, and the maytansinoid drug DM1. Trastuzumab alone lacks this attached payload; administering trastuzumab alongside an independent chemotherapy drug does not create an ADC. The antibody component can nevertheless retain pharmacological activity: in T-DM1 it both recognizes HER2 and inhibits HER2-associated signaling, while the attached DM1 provides an additional cytotoxic mechanism. (cancer.gov)\n\nADCs belong to the broader category of immunoconjugates, in which an immune-targeting component is linked to another functional substance. That category also includes antibody–radionuclide constructs used in radioimmunotherapy, where radiation provides the destructive action, and antibody-based immunotoxins carrying toxic proteins rather than small-molecule drugs. An example of the latter architecture is anti-EpCAM–Pseudomonas-exotoxin fusion protein, which joins an antibody fragment to a toxic protein. These constructs share antibody-directed targeting but differ in the nature of the delivered agent; they are therefore not treated here as interchangeable forms of small-molecule ADC therapy. (cancer.gov)\n\nThe principal scope of this article is oncology ADCs with cytotoxic small-molecule payloads. This boundary corresponds to the scope of the US Food and Drug Administration’s March 2024 guidance, Clinical Pharmacology Considerations for Antibody-Drug Conjugates. The guidance explicitly cautions that its principles may not apply to conjugates with other payload types or to indications outside oncology. Thus, antibody targeting alone does not establish that a construct has the same mechanisms, development requirements, or therapeutic boundaries as a cytotoxic cancer ADC; those depend also on the attached agent and intended use. (fda.gov)"
    },
    {
      "heading": "Historical Development and Regulatory Milestones",
      "text": "Gemtuzumab ozogamicin (Mylotarg), initially designated CMA-676, brought antibody-directed delivery of a potent cytotoxic drug into clinical use. It combined a humanized anti-CD33 monoclonal antibody with a calicheamicin derivative: recognition of CD33 enabled cellular uptake and delivery of a drug that causes DNA double-strand breaks. Its development therefore tested whether antigen recognition could translate into clinically useful drug delivery in acute myeloid leukemia (AML), rather than merely identify malignant cells. On May 17, 2000, the US Food and Drug Administration (FDA) granted accelerated approval for CD33-positive AML in first relapse in patients aged 60 years or older who were not considered candidates for other cytotoxic chemotherapy. The approved regimen was \\(9\\,\\mathrm{mg/m^2}\\), administered twice, 14 days apart; the evidence rested on remission responses rather than a randomized demonstration of improved survival. (pmc.ncbi.nlm.nih.gov)\n\nThe required confirmatory study, S0106, evaluated a different setting: previously untreated adults aged 60 years or younger received daunorubicin and cytarabine with or without gemtuzumab ozogamicin, given at \\(6\\,\\mathrm{mg/m^2}\\) during induction. This randomized trial failed to establish the anticipated clinical benefit and showed more fatal induction toxicities in the conjugate-containing group—5.8%, compared with 1.3% in the control group. Gemtuzumab ozogamicin was voluntarily withdrawn from the US market in 2010. The withdrawal thus followed an unfavorable confirmatory assessment of efficacy and safety, not simply the emergence of a manufacturing problem or the abandonment of CD33 targeting. (accessdata.fda.gov)\n\nIts return on September 1, 2017, depended on new evidence and revised dosing, rather than reinstatement of the original regimen. In ALFA-0701, a French randomized study of newly diagnosed AML, induction treatment incorporated fractionated gemtuzumab ozogamicin at \\(3\\,\\mathrm{mg/m^2}\\) on days 1, 4, and 7 alongside daunorubicin and cytarabine. The FDA-approved labeling reported median event-free survival of 17.3 months with gemtuzumab ozogamicin versus 9.5 months with chemotherapy alone, with a hazard ratio of 0.56. For relapsed disease, MyloFrance-1 provided evidence for the same fractionated induction schedule: 15 of 57 patients achieved complete remission. The 2017 approval covered newly diagnosed CD33-positive AML in adults and relapsed or refractory CD33-positive AML in patients aged at least two years. These supporting studies distinguished lower individual doses and fractionated administration from both the original monotherapy schedule and S0106. (purplebooksearch.fda.gov)\n\nLater development extended ADC use beyond hematologic malignancies and broadened the expression levels considered sufficient for targeting. Trastuzumab deruxtecan received US accelerated approval on December 20, 2019, for unresectable or metastatic HER2-positive breast cancer after at least two previous anti-HER2-based regimens in the metastatic setting. On August 5, 2022, results from DESTINY-Breast04 supported approval for previously treated unresectable or metastatic HER2-low breast cancer—a population historically classified as HER2-negative for treatment purposes. On January 27, 2025, the FDA further approved its use in hormone receptor-positive, HER2-low or HER2-ultralow advanced breast cancer progressing after one or more endocrine therapies in the metastatic setting. The latter indication defined HER2-ultralow as an immunohistochemistry score of 0 with membrane staining. These were product- and trial-specific expansions of biomarker eligibility, not evidence that all HER2-directed conjugates were interchangeable at low target expression. (aacrjournals.org)"
    },
    {
      "heading": "Antigen Selection and Antibody Design",
      "text": "The antibody recognizes an accessible epitope on a cell-surface antigen, making antigen expression the molecular basis of selective binding rather than cancer diagnosis alone. HER2, Trop-2, and nectin-4 illustrate how different surface proteins can serve as delivery addresses. The National Cancer Institute’s phase II ADC MATCH trial investigates trastuzumab deruxtecan, sacituzumab govitecan, and enfortumab vedotin against these three targets, respectively. Its screening protocol uses RNA expression testing followed by confirmation of protein expression through immunohistochemistry before treatment-cohort assignment. These are investigational biomarker criteria within a trial, not universal eligibility rules for the respective drugs. (fda.gov)\n\nAntigen abundance and antigen heterogeneity describe different properties. Abundance concerns how much target is available on a cell; heterogeneity concerns its distribution among cells or samples. Between-tumor variation means that separate specimens have different overall expression levels. Intratumoral heterogeneity means that strongly expressing, weakly expressing, and antigen-negative cells coexist within one lesion; an average tissue measurement does not describe that spatial mixture. In their 2016 study of DS-8201a, subsequently named trastuzumab deruxtecan, Yusuke Ogitani and colleagues distinguished high- and low-HER2 patient-derived models from deliberately mixed HER2-positive and HER2-negative cell populations. These models address different targeting questions: whether a conjugate acts at lower overall expression, and whether it can affect antigen-negative neighbors within a heterogeneous tumor. Payload-dependent effects on neighboring cells can modify the consequences of this heterogeneity without changing the antibody’s antigen specificity. (pubmed.ncbi.nlm.nih.gov)\n\nSpecificity, binding affinity, and tissue penetration are also distinct. Specificity concerns which molecular structure is recognized; affinity concerns the strength of an individual binding interaction. Increasing affinity does not necessarily improve delivery throughout a solid tumor. In a 2011 experimental study using anti-HER2 antibodies recognizing the same epitope, Stephen Rudnick and colleagues found that high-affinity antibodies could undergo greater internalization and degradation near their entry sites, restricting deeper penetration. This “binding-site barrier” connects antibody design to antigen density and turnover: strong local retention may coexist with uneven exposure elsewhere in the lesion. Antigen selection and antibody optimization therefore cannot be reduced to maximizing target expression or binding strength independently. (pubmed.ncbi.nlm.nih.gov)\n\nThe targeting component may be a full-length IgG, an antibody fragment, or an engineered combination of binding units. MEDI4276 provides a documented investigational example of a bispecific format more precisely described as biparatopic: it recognizes two different epitopes on the same antigen, rather than two different antigens. Its tetravalent structure joins trastuzumab-derived single-chain variable fragments to the heavy chains of the anti-HER2 antibody 39S, providing binding sites for HER2 extracellular subdomains 4 and 2. This arrangement crosslinks adjacent receptors and promotes receptor clustering and internalization. In the phase I study reported by Mark Pegram and colleagues in 2021, 47 patients with advanced HER2-positive breast or gastric cancer received MEDI4276. The study documented antitumor activity but substantial tolerability limitations; it evaluated an experimental construct, not an established treatment. (pmc.ncbi.nlm.nih.gov)\n\nAn antibody may function principally as a carrier, or its own pharmacological activity may contribute alongside payload delivery. FDA guidance explicitly recognizes the carrier-only case. Conversely, experiments by Teemu Junttila and colleagues, published online in 2010, showed that trastuzumab emtansine retained activities of unconjugated trastuzumab, including inhibition of HER2-associated PI3K–AKT signaling, inhibition of HER2 shedding, and Fc-receptor-mediated engagement of immune cells capable of antibody-dependent cellular cytotoxicity. Thus, target binding can support both delivery and antibody-mediated biological effects; their relative contributions require evaluation for the particular conjugate rather than inference from antigen recognition alone. (fda.gov)"
    },
    {
      "heading": "Linker and Payload Chemistry",
      "text": "Linker chemistry determines both the stability of the circulating conjugate and the chemical identity of the drug-containing products generated during degradation. Cleavable linkers contain a release trigger, such as a protease-sensitive peptide, an acid-sensitive hydrazone, or a reducible disulfide; noncleavable linkers instead depend principally on degradation of the antibody to produce an active drug–linker–amino-acid catabolite. These are different release strategies, not a simple ranking of potency. In 2008, Gail D. Lewis Phillips and colleagues compared trastuzumab–maytansinoid constructs and found that the nonreducible thioether-linked trastuzumab–DM1 showed superior activity to the disulfide-linked constructs tested in their preclinical models. The result illustrates why linker stability and payload activity must be evaluated together. (pubmed.ncbi.nlm.nih.gov)\n\nProtease-cleavable designs can incorporate a self-immolative spacer between the peptide trigger and the payload. In the valine–citrulline–p-aminobenzyloxycarbonyl system, lysosomal proteolysis initiates spacer fragmentation, releasing free drug without requiring complete antibody degradation. Stability before cleavage remains a separate requirement: premature release changes where the cytotoxic compound is delivered. Svetlana Doronina and colleagues reported in 2003 that peptide-linked monomethyl auristatin E conjugates were substantially more stable in buffers and plasma than the hydrazone-linked auristatin constructs they examined. Experiments with site-specific auristatin conjugates subsequently showed that the antibody attachment site could also alter the plasma stability of a cleavable linker, even when its release chemistry was otherwise retained. (pmc.ncbi.nlm.nih.gov)\n\nAuristatins and maytansinoids are chemically distinct small-molecule payload families, rather than modifications of the antibody’s protein sequence. Auristatin derivatives—including monomethyl auristatin E (MMAE) and monomethyl auristatin D (MMAD)—inhibit tubulin-dependent microtubule assembly. DM1 is a thiol-containing maytansinoid with antitubulin activity. In trastuzumab emtansine, DM1 is attached through an SMCC-derived noncleavable thioether linker. Antibody degradation therefore does not simply liberate unmodified DM1: an important active product is lysine–MCC–DM1, also described as Lys-SMCC-DM1, which retains both linker material and an antibody-derived lysine residue. Its biological activity must consequently be distinguished from that of free DM1. (pmc.ncbi.nlm.nih.gov)\n\nDeruxtecan-based conjugates use a different payload class: exatecan-derived topoisomerase I inhibitors. In the DS-8201a construct, subsequently named trastuzumab deruxtecan, an anti-HER2 antibody is connected to the exatecan derivative DXd through a cleavable glycine–glycine–phenylalanine–glycine tetrapeptide-based linker. This replaces the microtubule-directed chemistry of DM1 with a payload directed against an enzyme involved in DNA topology. Yusuke Ogitani and colleagues’ 2016 studies documented this drug-linker platform and investigated related DXd conjugates directed against CD30, CD33, CD70, and B7-H3, demonstrating that the payload-linker technology was experimentally applicable to multiple antibodies. These were preclinical findings, not evidence that the resulting constructs were clinically interchangeable. (aacrjournals.org)\n\nThe released chemical species also determines how readily a payload crosses a cell membrane. In Ogitani and colleagues’ 2016 comparison, the membrane-permeable DXd species released from DS-8201a had a distribution coefficient, \\(\\log D\\), of 2.3 at pH 7.4, compared with 0.2 for Lys-SMCC-DM1, and showed substantially greater permeability in an artificial-membrane assay. Such permeability permits drug to leave a targeted cell and potentially enter neighboring cells, providing a chemical basis for bystander killing. Low passive permeability does not, however, imply intracellular inactivity: Ryuto Tomabechi and colleagues demonstrated in 2022 that the lysosomal transporter SLC46A3 directly transports Lys-SMCC-DM1. Linker remnants and retained amino acids can therefore change both membrane passage and transport requirements without abolishing payload activity. (onlinelibrary.wiley.com)"
    },
    {
      "heading": "Conjugation and Molecular Heterogeneity",
      "text": "The drug-to-antibody ratio (DAR) describes the number of payload molecules attached to an antibody. An individual molecule has an integer loading, whereas a preparation is commonly described by its mean DAR. If \\(f_n\\) is the molar fraction of antibody molecules carrying \\(n\\) payloads, the mean is \\(\\overline{\\mathrm{DAR}}=\\sum_n n f_n\\), with \\(\\sum_n f_n=1\\). This average does not specify the loading distribution: as a mathematical example, equal proportions of DAR-2 and DAR-6 molecules give the same mean of four as a uniform DAR-4 population. Unconjugated antibody, when included in the preparation being characterized, contributes a DAR-0 fraction; the FDA’s March 2024 clinical-pharmacology guidance distinguishes this from ADC molecules carrying at least one payload. (fda.gov)\n\nConventional conjugation exploits native amino-acid side chains, particularly surface-accessible lysine amino groups or cysteine thiols exposed by reducing interchain disulfide bonds. Because several residues can react, the resulting material may vary both in payload number and in attachment position. These are distinct dimensions of heterogeneity: even molecules with identical DAR can carry their drugs at different sites. Site-specific approaches instead introduce selected reactive groups, such as engineered cysteines or chemically distinctive nonnative amino acids, to restrict attachment to predetermined positions. They therefore provide control over both stoichiometry and location, rather than merely narrowing the range of drug loading. (pmc.ncbi.nlm.nih.gov)\n\nNonnative amino-acid incorporation provides an experimentally demonstrated route to this control. In 2012, Jun Y. Axup and colleagues incorporated para-acetylphenylalanine into an anti-HER2 Fab fragment and full-length IgG, then coupled an auristatin derivative through an oxime linkage. The introduced side-chain ketone reacts selectively with an aminooxy group on the drug-linker, providing chemistry distinct from that of the usual antibody residues. In 2014, Feng Tian and colleagues extended the approach to stable Chinese hamster ovary cell lines producing modified antibodies at titers exceeding \\(1\\ \\mathrm{g/L}\\). Using anti-HER2 and anti-5T4 antibodies, they attached hydroxylamine-functionalized monomethyl auristatin D through either protease-cleavable or noncleavable linkers. Selected noncleavable conjugates showed improved stability and antitumor activity relative to cysteine-linked comparators in preclinical experiments. (pubmed.ncbi.nlm.nih.gov)\n\nAttachment site and linker chemistry cannot be evaluated independently. In a 2012 study, Ben-Quan Shen and colleagues introduced cysteines at three sites on an anti-HER2 antibody with different solvent accessibility and local charge. At the highly exposed site, maleimide-linked material was lost through exchange with plasma thiols, including those in albumin, cysteine, and glutathione. A partially accessible, positively charged site instead promoted hydrolysis of the linker’s succinimide ring, suppressing that exchange. These differences affected conjugate stability and therapeutic activity in a mouse mammary-tumor model: specifying an attachment residue alone did not establish the stability of the antibody–linker interface. (pubmed.ncbi.nlm.nih.gov)\n\nGreater loading likewise does not invariably improve biological performance. Kevin J. Hamblett and colleagues separated anti-CD30–monomethyl auristatin E conjugates carrying two, four, or eight drugs per antibody in a 2004 study. Although higher loading increased cell-killing potency in vitro, DAR-4 and DAR-8 preparations had comparable antitumor activity at equal antibody doses in mouse xenografts. The DAR-8 preparation cleared approximately three times faster than DAR-4, while the maximum tolerated antibody dose of DAR-4 was twice that of DAR-8. These results establish a loading-dependent trade-off for that antibody–linker–payload combination, rather than a universal optimal DAR for all conjugates. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Cellular Uptake, Drug Release, and Bystander Effects",
      "text": "The principal uptake pathway begins when the antibody component binds its target antigen on the cell surface, followed by internalization and intracellular processing that makes the cytotoxic payload available. This sequence does not imply that every conjugate releases the same chemical species or uses the same intracellular transport machinery. Trastuzumab emtansine (T-DM1), for example, binds subdomain IV of HER2 and undergoes receptor-mediated internalization followed by lysosomal degradation. Its drug-containing catabolites disrupt microtubule networks, producing cell-cycle arrest and apoptotic cell death. Thus, antigen recognition initiates delivery, but intracellular processing is also necessary for payload action. (fda.gov)\n\nFor T-DM1, the noncleavable linker remains attached to the payload during antibody degradation, producing the active catabolite Lys-SMCC-DM1, which contains a lysine residue, linker-derived material, and DM1. Release into the lysosomal lumen is not the final delivery step: the catabolite must reach the cytoplasm to act on tubulin. In a 2022 study, Ryuto Tomabechi and colleagues demonstrated that the lysosomal membrane protein SLC46A3 directly transports Lys-SMCC-DM1. They characterized SLC46A3 as a proton-coupled transporter and found that pharmacological inhibitors of its transport activity attenuated T-DM1 cytotoxicity. These experiments distinguish degradation of the conjugate from transport of its active product across the lysosomal membrane; the latter is a specific mechanistic requirement rather than simple passive diffusion of freely released DM1. (pubmed.ncbi.nlm.nih.gov)\n\nBystander killing occurs when released payload affects neighboring cells, including cells with little or no target-antigen expression. In experiments with DS-8201a, subsequently known as trastuzumab deruxtecan, its released topoisomerase I inhibitor DXd crossed membranes much more readily than Lys-SMCC-DM1. This difference provides a mechanism by which antigen-positive cells can serve as local sources of cytotoxic drug for surrounding antigen-negative cells. (pubmed.ncbi.nlm.nih.gov)\n\nIn 2016, Yusuke Ogitani and colleagues tested HER2-positive KPL-4 cells together with HER2-negative MDA-MB-468 cells. After five days at 10 nM, DS-8201a killed both populations; T-DM1 and a comparator carrying a poorly permeable DXd derivative killed the HER2-positive population without comparable bystander killing. MDA-MB-468 cells cultured alone were insensitive to the intact conjugates, supporting indirect payload delivery in the mixed culture. (onlinelibrary.wiley.com)\n\nThe researchers also implanted mice with mixtures of HER2-positive NCI-N87 cells and luciferase-marked, HER2-negative MDA-MB-468 cells. DS-8201a reduced the luciferase signal, indicating suppression of the antigen-negative population; the comparators did not. Separate HER2-negative tumors on the opposite flank were not similarly suppressed, supporting a local effect in this model. These cell-culture and animal findings establish mechanistic evidence, not clinical proof that bystander killing itself improves patient outcomes. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Pharmacokinetics and Clinical Pharmacology",
      "text": "Clinical development measures several circulating analytes rather than treating an ADC as a single pharmacokinetic entity. Conjugated antibody comprises antibody molecules carrying at least one payload molecule; total antibody includes both conjugated and unconjugated antibody; unconjugated payload is the small-molecule drug no longer attached to antibody. These measurements describe different pools: total antibody does not establish how much remains drug-bearing, while unconjugated payload requires separate quantification. The US Food and Drug Administration’s March 2024 guidance recommends validated assays beginning in first-in-human studies. Later omission of an analyte requires justification—for example, total-antibody measurement may become unnecessary when the antibody acts only as a carrier and its concentrations closely correlate with those of the conjugate. (fda.gov)\n\nDose–exposure analysis characterizes how administered dose relates to circulating concentrations; exposure–response analysis relates those concentrations to efficacy and adverse effects. The FDA recommends examining the conjugate and relevant constituents across multiple doses or schedules early in development. Their contributions need not coincide: changing dosage to normalize payload exposure in a patient subgroup can also change conjugate exposure and therefore efficacy. Exposure–response findings support both regimen selection and evaluation of dose adjustments, rather than assuming that a dose appropriate for one constituent necessarily optimizes the complete product. (fda.gov)\n\nHepatic and renal impairment can affect the constituents differently. Population pharmacokinetic analyses or dedicated studies assess these effects, with attention to payload elimination and the exposure–toxicity relationship. (fda.gov) Brentuximab vedotin provides a quantitative example. Studies described in its 2023 US prescribing information administered 1.2 mg/kg to patients with impaired organ function. Unconjugated monomethyl auristatin E (MMAE) exposure, measured by area under the concentration–time curve (AUC), was approximately twice as high in the three patients with severe renal impairment—creatinine clearance below 30 mL/min—as in patients with normal renal function. Mild or moderate renal impairment did not meaningfully alter MMAE AUC. In seven patients with hepatic impairment, comprising one Child–Pugh A, five Child–Pugh B, and one Child–Pugh C patient, MMAE AUC was approximately 2.3-fold higher than in patients with normal hepatic function. (accessdata.fda.gov)\n\nDrug–drug interaction assessment distinguishes the payload’s ability to inhibit or induce metabolic pathways from its susceptibility as a substrate of an enzyme or transporter. Low circulating payload concentrations may limit inhibition or induction, but do not remove substrate-related risk: another drug can reduce payload clearance, and even a modest exposure increase may affect safety. In-vitro enzyme and transporter studies therefore inform whether clinical interaction studies are needed. (fda.gov) For brentuximab vedotin, coadministration with the strong CYP3A4 inhibitor ketoconazole increased MMAE exposure by approximately 34%, whereas the strong inducer rifampin reduced it by approximately 46%. These findings concern the released payload rather than establishing an equivalent change in conjugated-antibody exposure. (accessdata.fda.gov)\n\nImmunogenicity assessment addresses immune responses against the antibody, conjugated drug, or linker-associated structures. Anti-drug antibodies are evaluated for their possible effects on pharmacokinetics, safety, and efficacy; their detection alone does not establish a clinically consequential effect. The FDA recommends a multitiered testing approach, and more than one assay may be needed to identify which constituent the antibodies recognize. This distinction matters because an assay directed only at the antibody component may not characterize responses to structures introduced through conjugation. (fda.gov)"
    },
    {
      "heading": "Manufacturing and Analytical Characterization",
      "text": "Manufacture combines antibody production and purification, separate preparation of the drug–linker intermediate, conjugation, and purification of the resulting product. A documented example is the 2014 study by Feng Tian and colleagues, who produced antibodies containing the nonnative amino acid para-acetylphenylalanine in Chinese hamster ovary cells at titers exceeding 1 g/L. The antibodies were purified by protein A affinity and cation-exchange chromatography. A separately prepared monomethyl auristatin D derivative carried a linker terminating in an alkoxyamine, which reacted with the engineered ketone group to form an oxime bond. Ultrafiltration removed residual small-molecule reagent, yielding nearly homogeneous conjugates with two drugs per antibody and reported conjugation yields above 95%. These results describe a particular manufacturing strategy, rather than specifications applicable to all ADCs. (pmc.ncbi.nlm.nih.gov)\n\nAnalytical characterization distinguishes several attributes that cannot be reduced to a single purity measurement. Identity concerns whether the expected antibody, linker–payload structure, and covalent conjugate are present; attachment-site distribution concerns which residues carry drug; drug loading concerns the number and distribution of payloads per antibody; and residual constituents include unconjugated antibody and free drug or drug–linker species. Site-specific synthesis does not necessarily eliminate loading heterogeneity before purification. In a 2024 study, Michihiko Aoyama and colleagues separated preparations containing drug-to-antibody ratios (DARs) of 0, 1, and 2 by hydrophobic interaction chromatography, isolating the DAR-2 fraction. Residual small-molecule material requires a separate assay: a 2016 study developed liquid chromatography with multiple-reaction-monitoring mass spectrometry to quantify free linker–payload down to 10 nM and used it to monitor removal during tangential-flow filtration. (pubmed.ncbi.nlm.nih.gov)\n\nLiquid chromatography and mass spectrometry provide complementary separation and structural information. Hydrophobic interaction chromatography can resolve drug-loading species and support calculation of average DAR from integrated peak areas. Intact-mass measurements identify mass increments consistent with attached payloads, while analysis of antibody subunits provides more localized structural information. In 2017, Reiko Iizuka and colleagues assessed cysteine-conjugated ADCs with low, moderate, and high loading using hydrophobic interaction chromatography with ultraviolet detection and native size-exclusion chromatography–mass spectrometry; the two approaches produced comparable DAR estimates. Their two-dimensional workflow transferred individual hydrophobic-interaction peaks to reversed-phase chromatography and used subunit mass analysis to investigate conjugation sites. An average DAR alone therefore does not establish the proportions of differently loaded molecules or distinguish positional variants carrying the same number of drugs. (pubmed.ncbi.nlm.nih.gov)\n\nStability assessment must distinguish preservation of the antibody structure from preservation of its attached drug. Thermal measurements can probe changes in protein unfolding, whereas serial measurements of loading and released small molecules investigate linker integrity and payload loss. Aoyama and colleagues, for example, measured thermal transitions separately from linker stability, following DAR after incubation under cell-culture conditions for 0, 6, 24, 48, and 96 hours. Such experiments address specific degradation mechanisms; they do not by themselves establish storage shelf life. The ICH Q5E guideline calls for real-time and accelerated stability comparisons after manufacturing changes and identifies stress studies as potentially useful for detecting altered degradation pathways. (pubmed.ncbi.nlm.nih.gov)\n\nManufacturing changes consequently require a comparability exercise rather than confirmation that the mean DAR remains unchanged. A published study of the investigational anti-HER2 conjugate ARX788 examined changes in drug-substance and drug-product manufacturing sites, formulation, and dosage form through analytical comparisons. Under ICH Q5E, comparability considers physicochemical properties, biological activity, impurity profiles, and stability; sufficiently informative quality data can establish comparability without additional clinical studies. Pharmacokinetic bridging addresses a different question—whether pre-change and post-change materials behave comparably after administration—and may be required when analytical evidence leaves relevant uncertainty. Similar circulating exposure cannot substitute for identifying a new impurity or an altered distribution of molecular variants in the manufactured material. (pmc.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Clinical Applications and Biomarker Assessment",
      "text": "In acute myeloid leukemia (AML), gemtuzumab ozogamicin links treatment selection to expression of the cell-surface antigen CD33. On September 1, 2017, the United States Food and Drug Administration (FDA) approved it for adults with newly diagnosed CD33-positive AML and for patients aged two years or older with relapsed or refractory CD33-positive AML. These were the populations covered by that approval, rather than all patients with AML. The newly diagnosed setting included use with induction chemotherapy, illustrating that an ADC may be incorporated into a multidrug regimen rather than administered only as a replacement for conventional cytotoxic treatment. (cancer.gov)\n\nIn breast cancer, trastuzumab deruxtecan has indications defined jointly by HER2 status, disease extent, and previous treatment. Its initial US accelerated approval, on December 20, 2019, covered adults with unresectable or metastatic HER2-positive breast cancer after at least two previous anti-HER2-based regimens in the metastatic setting. On August 5, 2022, FDA approval extended to unresectable or metastatic HER2-low breast cancer after chemotherapy in the metastatic setting, or recurrence during or within six months after adjuvant chemotherapy. The latter indication established a treatment-eligible population outside the conventional HER2-positive category; it did not make every HER2-negative breast cancer eligible. (pubmed.ncbi.nlm.nih.gov)\n\nHER2 assessment distinguishes three different biological measurements. Immunohistochemistry (IHC) assesses protein expression in tumor tissue; in situ hybridization (ISH) assesses amplification of the ERBB2 gene; and molecular testing can identify an activating ERBB2 mutation. These are not interchangeable positive results. For breast-cancer treatment selection, HER2-positive disease is commonly identified as IHC 3+ or ISH-positive, whereas the HER2-low category used for trastuzumab deruxtecan is IHC 1+ or IHC 2+/ISH-negative. Thus, an IHC 2+ result requires its amplification result to distinguish these eligibility categories. A report stating only “HER2-negative” does not communicate the distinction between low expression and other negative results. (cancer.gov)\n\nVery-low expression acquired a further treatment-specific definition with the January 27, 2025, US approval of trastuzumab deruxtecan for unresectable or metastatic hormone receptor-positive, HER2-low or HER2-ultralow breast cancer progressing after one or more endocrine therapies in the metastatic setting. HER2-ultralow was defined as IHC 0 with membrane staining, not all IHC 0 disease. FDA also approved the Ventana PATHWAY anti-HER-2 (4B5) assay as a companion diagnostic for this category. In DESTINY-Breast06, which enrolled 866 patients and excluded previous chemotherapy for advanced or metastatic disease, median progression-free survival in the 713-patient HER2-low population was 13.2 months with trastuzumab deruxtecan versus 8.1 months with physician-selected chemotherapy. That estimate describes the HER2-low analysis, not the ultralow subgroup alone. These definitions and treatment-history requirements belong to the particular product and indication, rather than to HER2-directed ADCs collectively. (fda.gov)\n\nIn lung cancer, a different HER2 measurement determines eligibility. On August 11, 2022, the FDA granted accelerated approval to trastuzumab deruxtecan for adults with unresectable or metastatic non-small-cell lung cancer bearing an activating HER2 (ERBB2) mutation, detected by an FDA-approved test, after previous systemic therapy. This mutation-defined indication is distinct from selection by protein overexpression or gene amplification: the breast-cancer IHC categories cannot simply be transferred to this lung-cancer indication. (fda.gov)\n\nADC MATCH extends biomarker assessment into a phase II, multi-substudy clinical trial for advanced or metastatic solid tumors. It investigates sacituzumab govitecan for Trop-2 expression, enfortumab vedotin for nectin-4 expression, and trastuzumab deruxtecan for HER2 expression, using RNA and protein testing in its screening framework. Protocol-specific criteria include nectin-4 IHC 2+ or 3+ for the enfortumab cohort and HER2 IHC 2+ or 3+, together with qualifying RNA expression, for the trastuzumab deruxtecan cohort. These thresholds define research enrollment; they neither establish efficacy across every enrolled tumor type nor constitute additional regulatory indications. (cancer.gov)"
    },
    {
      "heading": "Safety and the Therapeutic Window",
      "text": "The therapeutic window of an antibody–drug conjugate (ADC) is the range of exposures that produces antitumor activity without unacceptable toxicity. Selective recognition of an antigen does not establish complete tumor specificity: normal cells can express the same target, and uptake can also occur independently of antigen binding. Circulating payload released from the conjugate provides another potential route of exposure outside the tumor. Experimental work on lung injury has implicated antigen-independent uptake through Fcγ receptors on alveolar macrophages, although such findings do not establish a single mechanism for all ADC-associated pulmonary toxicity. Thus, targeting can alter drug distribution without conferring absolute protection on healthy tissues. (pmc.ncbi.nlm.nih.gov)\n\nSafety assessment distinguishes the administered conjugate from its circulating constituents and degradation products. The intact ADC determines where conjugated drug is delivered, whereas unconjugated payload and pharmacologically active drug-containing metabolites may have different distributions, elimination pathways, and toxic effects. The US Food and Drug Administration’s March 2024 guidance calls for measurement of the ADC and relevant constituents beginning in first-in-human studies, with quantifiable active metabolites included in subsequent exposure–response analyses. Total antibody concentration alone is not necessarily an adequate surrogate for these exposures. For assessment of QTc prolongation—a measure relevant to delayed cardiac repolarization—the unconjugated payload and active metabolites are usually the principal analytes, rather than the antibody component. (fda.gov)\n\nDose selection therefore depends on both antitumor and toxicity relationships, not simply on increasing delivery to antigen-positive cells. FDA guidance describes evaluation across a wide dosage range early in development to distinguish the contributions of the conjugate and its active constituents. Low circulating concentrations of unconjugated payload do not automatically make them clinically unimportant: a relatively small increase caused by inhibition of its elimination can affect safety when the payload is highly potent. Consequently, exposure–toxicity analyses and interaction assessments address the relevant constituent separately from the conjugate as a whole. (fda.gov)\n\nTrastuzumab deruxtecan illustrates a product-specific risk of interstitial lung disease and pneumonitis, including fatal events. In the original DESTINY-Lung01 report, published online in 2021 by Bob T. Li and colleagues, 91 patients with metastatic HER2-mutant non-small-cell lung cancer refractory to standard treatment received 6.4 mg/kg intravenously every three weeks. At a median follow-up of 13.1 months, adjudicated drug-related interstitial lung disease occurred in 26% of patients and caused two deaths. Grade 3 or higher drug-related adverse events occurred in 46%, with neutropenia reported at that severity in 19%. These frequencies describe that population, regimen, and analysis; they are not general incidence estimates for every trastuzumab deruxtecan indication or for ADCs collectively. (pubmed.ncbi.nlm.nih.gov)\n\nImmunogenicity is another product-specific dimension of safety. Immune responses can recognize the antibody, linker, or conjugated payload, and anti-drug antibodies may affect exposure, safety, or efficacy. FDA describes a tiered testing strategy, potentially requiring multiple assays to identify the recognized component. A positive assay result does not by itself establish clinical harm; interpretation depends on its relationship to pharmacokinetic changes and observed outcomes. Likewise, adverse-event patterns and exposure–toxicity relationships established for one ADC cannot be assigned indiscriminately to another, even when the products share a target or payload family. (fda.gov)"
    },
    {
      "heading": "Resistance and Biological Limitations",
      "text": "Primary nonresponse, or intrinsic resistance, denotes insensitivity present before treatment; acquired resistance denotes loss of sensitivity after an initially responsive state. Experimental models distinguish these by comparing untreated, inherently insensitive cells with sensitive parental cells and derivatives selected under ADC exposure. In their 2018 study, Krista Kinneer and colleagues investigated both patterns using noncleavable conjugates and models of trastuzumab emtansine (T-DM1) resistance, including patient-derived xenografts. These models identified failures of intracellular drug handling in addition to limitations imposed by target expression. Resistance was not uniform even between breast cancer cell lines: a separate 2018 study found reduced HER2 and increased MDR1 drug-efflux activity in resistant KPL-4 cells, whereas loss of SLC46A3 and PTEN deficiency contributed in resistant BT-474M1 cells. (pubmed.ncbi.nlm.nih.gov)\n\nHeterogeneous antigen expression constrains delivery because cells within the same tumor can differ in their capacity to bind and internalize a targeted conjugate. Bystander killing can partly bypass this constraint when released payload crosses cell membranes, but its spatial reach is limited. In 2016, Yusuke Ogitani and colleagues showed that DS-8201a, subsequently named trastuzumab deruxtecan, killed both HER2-positive KPL-4 cells and neighboring HER2-negative MDA-MB-468 cells in coculture; T-DM1 did not produce comparable bystander killing. Mixed-cell xenografts likewise demonstrated suppression of the HER2-negative population. However, HER2-negative tumors implanted on the opposite side of the same mice were not suppressed. These experiments support local compensation for heterogeneous expression, not elimination of the need for accessible target-positive cells or effective payload delivery throughout separate tumor deposits. (pubmed.ncbi.nlm.nih.gov)\n\nLoss of the lysosomal transporter SLC46A3 provides a mechanistically specific example of resistance after uptake. Kinneer and colleagues screened expression of 43 lysosomal membrane-associated genes and tested functional dependence using EPHA2-, HER2-, and BCMA-directed conjugates. SLC46A3 loss reduced the activity of noncleavable ADCs carrying either DM1, a maytansinoid microtubule inhibitor, or SG3376, a pyrrolobenzodiazepine dimer with a different cytotoxic mechanism. Genetic inactivation and forced expression supported a causal role rather than a simple correlation. The investigators also reported restoration of sensitivity following SLC46A3 re-expression in resistant cells. Their 2018 conference report described a patient-derived breast-tumor xenograft with acquired T-DM1 resistance in which SLC46A3 expression was 92% lower than in the sensitive parental model; this was a model-specific measurement, not an estimate of resistance frequency in patients. (aacrjournals.org)\n\nThe relevant bottleneck is escape of an active drug-containing catabolite from the lysosome, rather than antibody binding alone. Ryuto Tomabechi and colleagues demonstrated in 2022 that SLC46A3 directly transports Lys-SMCC-DM1, a major T-DM1 catabolite, and that experimental inhibition of the transporter attenuates T-DM1 cytotoxicity. Consequently, successful antigen recognition and internalization need not yield sufficient cytoplasmic drug exposure. This requirement cannot be assigned indiscriminately to other ADCs: in Kinneer’s experiments, changing SLC46A3 expression did not alter activity of conjugates carrying noncleavable MMAF or the cleavable pyrrolobenzodiazepine linker-payload SG3249. Thus, neither a shared antigen nor classification as a noncleavable conjugate establishes a shared resistance mechanism; the released chemical species and its intracellular transport requirements must also match. (pubmed.ncbi.nlm.nih.gov)"
    },
    {
      "heading": "Experimental Evaluation and Research Directions",
      "text": "Cell-based binding assays test whether conjugation preserves antibody recognition of its target antigen, whereas concentration–response cytotoxicity experiments measure the resulting loss of cell viability; binding alone does not establish effective payload delivery. Comparisons across high- and low-antigen cell lines assess expression-dependent activity. Co-cultures ask a different question: whether target-expressing cells enable killing of neighboring target-negative cells. Human-tumor xenografts in mice measure tumor growth or regression under whole-animal exposure, while pharmacokinetic studies assess circulating persistence and conjugate stability. These endpoints are complementary: tumor regression does not by itself identify which molecular modification improved delivery or distinguish increased exposure from increased cellular potency. (pmc.ncbi.nlm.nih.gov)\n\nSite-specific attachment permits controlled comparisons of conjugation chemistry and position. In 2014, Feng Tian and colleagues incorporated the nonnative amino acid para-acetylphenylalanine into anti-HER2 and anti-5T4 antibodies, then attached hydroxylamine-functionalized monomethyl auristatin D through oxime bonds. Selected noncleavable conjugates showed improved activity and pharmacokinetic stability relative to cysteine-linked comparators in rodent studies; with protease-cleavable linkers, attachment position affected stability. An anti-HER2 construct was tolerated at doses up to 90 mg/kg in a single-dose rat study. These were construct- and model-specific findings, not evidence of a human therapeutic advantage. (pmc.ncbi.nlm.nih.gov)\n\nEngineered binding formats likewise require separate tests of mechanism, exposure, and tolerability. MEDI4276 combined a tetravalent, biparatopic antibody recognizing two HER2 epitopes with a tubulysin payload, seeking to promote receptor clustering and internalization. Its first-in-human phase I study treated 47 patients with advanced HER2-positive breast or gastric cancer. Investigators reported one complete response and two partial responses, all in patients with breast cancer, but also dose-limiting liver-function abnormalities; the maximum tolerated dose was exceeded at 0.9 mg/kg. The clinical report could not attribute toxicity definitively to the payload, binding architecture, conjugation chemistry, or their combination. Increased structural complexity therefore remained an experimental variable rather than a demonstrated clinical advantage. (pmc.ncbi.nlm.nih.gov)\n\nQuantitative modeling extends co-culture experiments beyond a single endpoint viability measurement. In 2016, Aman P. Singh, Sharad Sharma, and Dhaval K. Shah studied a trastuzumab–vc–MMAE research conjugate using GFP-labeled MCF7 cells as the antigen-negative population and N87, BT474, or SKBR3 cells as HER2-expressing populations. Bystander killing increased with the fraction of antigen-positive cells and with their target-expression level, but appeared only after a measurable lag. It could also diminish as the antigen-positive population declined. Their pharmacodynamic model combined separate cell-distribution models for the two populations, relating mixture composition to the time course and extent of killing. Such modeling characterizes a particular experimental system; it does not establish that the same parameters describe spatially organized human tumors. (pubmed.ncbi.nlm.nih.gov)\n\nBiomarker-directed clinical investigation tests another evidentiary step: whether molecular selection identifies patients who respond. The phase II ADC MATCH protocol screens advanced or metastatic solid tumors for target RNA expression, followed by immunohistochemical confirmation of target protein. Treatment cohorts match Trop-2 to sacituzumab govitecan, nectin-4 to enfortumab vedotin, and HER2 to trastuzumab deruxtecan. Objectives include RNA–protein concordance and objective response rates; paired pretreatment and on-treatment biopsies support biological analyses. These protocol-defined assignments are research eligibility criteria, not independent regulatory indications. (cancer.gov)\n\nGemtuzumab ozogamicin illustrates why clinical activity and initial authorization do not eliminate the need for confirmatory evidence. After US accelerated approval on May 17, 2000, its confirmatory trial failed to establish clinical benefit and raised safety concerns, leading to withdrawal from the US market in 2010. Approval on September 1, 2017, followed additional clinical evidence supporting revised dosing, including a lower, fractionated schedule. Its history makes dose, schedule, treatment combination, and patient population integral parts of the evidence—not details that can be inferred from preclinical activity or target expression alone. (accessdata.fda.gov)"
    }
  ],
  "links": [
    "antibody",
    "monoclonal-antibody",
    "antigen",
    "breast-cancer",
    "covalent-bond",
    "pharmacology",
    "chemotherapy",
    "dna",
    "leukemia",
    "randomized-controlled-trial",
    "biomarker",
    "epitope",
    "immunoglobulin-g",
    "protein",
    "microtubule",
    "cell-membrane",
    "amino-acid",
    "hydrolysis",
    "cell-cycle",
    "apoptosis",
    "pharmacokinetics",
    "enzyme",
    "chromatography",
    "mass-spectrometry",
    "gene",
    "mutation",
    "clinical-trial",
    "biopsy"
  ],
  "sources": [
    {
      "title": "Guidance Recap Podcast | Clinical Pharmacology Considerations for Antibody-Drug Conjugates",
      "url": "https://www.fda.gov/drugs/guidances-drugs/guidance-recap-podcast-clinical-pharmacology-considerations-antibody-drug-conjugates"
    },
    {
      "title": "Clinical Pharmacology Considerations for Antibody-Drug Conjugates: Guidance for Industry",
      "url": "https://www.fda.gov/media/155997/download"
    },
    {
      "title": "Definition of antibody-drug conjugate - NCI Dictionary of Cancer Terms",
      "url": "https://www.cancer.gov/publications/dictionaries/cancer-terms/def/antibody-drug-conjugate"
    },
    {
      "title": "Definition of ado-trastuzumab emtansine - NCI Drug Dictionary",
      "url": "https://www.cancer.gov/publications/dictionaries/cancer-drug/def/trastuzumab-emtansine"
    },
    {
      "title": "T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast Cancer",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2019/kadcyla-fda-breast-her2-adjuvant"
    },
    {
      "title": "Definition of immunoconjugate - NCI Dictionary of Cancer Terms",
      "url": "https://www.cancer.gov/publications/dictionaries/cancer-terms/def/immunoconjugate"
    },
    {
      "title": "Definition of radioimmunotherapy - NCI Dictionary of Cancer Terms",
      "url": "https://www.cancer.gov/publications/dictionaries/cancer-terms/def/radioimmunotherapy"
    },
    {
      "title": "NCI Dictionary of Cancer Terms",
      "url": "https://www.cancer.gov/publications/dictionaries/cancer-terms/"
    },
    {
      "title": "Clinical Pharmacology Considerations for Antibody-Drug Conjugates Guidance for Industry",
      "url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-pharmacology-considerations-antibody-drug-conjugates-guidance-industry"
    },
    {
      "title": "FDA Approval Summary: Mylotarg for Treatment of Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6192608/"
    },
    {
      "title": "Gemtuzumab Ozogamicin: FDA Statistical Review",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000StatR.pdf"
    },
    {
      "title": "MYLOTARG (gemtuzumab ozogamicin) for injection: 2017 Prescribing Information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761060lbl.pdf"
    },
    {
      "title": "Purple Book: Mylotarg Product Details",
      "url": "https://purplebooksearch.fda.gov/index.cfm?blaNo=761060&event=productdetails"
    },
    {
      "title": "Trastuzumab Deruxtecan for Metastatic HER2-Low Breast Cancer",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2022/enhertu-her2-low-breast-cancer"
    },
    {
      "title": "FDA approves fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HR-positive, HER2-low or HER2-ultralow breast cancer",
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-hr-positive-her2-low-or-her2"
    },
    {
      "title": "Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)",
      "url": "https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-01903"
    },
    {
      "title": "Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27166974/"
    },
    {
      "title": "Influence of affinity and antigen internalization on the uptake and penetration of Anti-HER2 antibodies in solid tumors",
      "url": "https://pubmed.ncbi.nlm.nih.gov/21406401/"
    },
    {
      "title": "First-in-Human, Phase 1 Dose-Escalation Study of Biparatopic Anti-HER2 Antibody–Drug Conjugate MEDI4276 in Patients with HER2-positive Advanced Breast or Gastric Cancer",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC9398097/"
    },
    {
      "title": "Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer",
      "url": "https://pubmed.ncbi.nlm.nih.gov/20730488/"
    },
    {
      "title": "Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate",
      "url": "https://pubmed.ncbi.nlm.nih.gov/19010901/"
    },
    {
      "title": "The effect of different linkers on target cell catabolism and pharmacokinetics/pharmacodynamics of trastuzumab maytansinoid conjugates",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22408268/"
    },
    {
      "title": "A general approach to site-specific antibody drug conjugates",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC3918752/"
    },
    {
      "title": "Development of potent monoclonal antibody auristatin conjugates for cancer therapy",
      "url": "https://pubmed.ncbi.nlm.nih.gov/12778055/?dopt=Abstract"
    },
    {
      "title": "Wide application of a novel topoisomerase I inhibitor-based drug conjugation technology",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27599744/"
    },
    {
      "title": "SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1",
      "url": "https://pubmed.ncbi.nlm.nih.gov/36741448/"
    },
    {
      "title": "A general approach to site-specific antibody drug conjugates",
      "url": "https://pubmed.ncbi.nlm.nih.gov/24443552/"
    },
    {
      "title": "Synthesis of site-specific antibody-drug conjugates using unnatural amino acids",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22988081/"
    },
    {
      "title": "Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates",
      "url": "https://pubmed.ncbi.nlm.nih.gov/22267010/"
    },
    {
      "title": "Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate",
      "url": "https://pubmed.ncbi.nlm.nih.gov/15501986/"
    },
    {
      "title": "KADCYLA prescribing information",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/125427s121lbl.pdf"
    },
    {
      "title": "ADCETRIS (brentuximab vedotin) US Prescribing Information, 2023",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125388s107lbl.pdf"
    },
    {
      "title": "Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity",
      "url": "https://pubmed.ncbi.nlm.nih.gov/39363433/"
    },
    {
      "title": "A simple LC/MRM-MS-based method to quantify free linker-payload in antibody-drug conjugate preparations",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27311685/"
    },
    {
      "title": "The Characterization of Drug-to-Antibody Ratio and Isoforms of ADCs Using LC and MS Technologies",
      "url": "https://pubmed.ncbi.nlm.nih.gov/28458283/"
    },
    {
      "title": "Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, Q5E",
      "url": "https://www.database.ich.org/sites/default/files/Q5E%20Guideline.pdf"
    },
    {
      "title": "Analytical comparability to evaluate impact of manufacturing changes of ARX788, an Anti-HER2 ADC in late-stage clinical development",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC10332591/"
    },
    {
      "title": "Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process, Q5E",
      "url": "https://database.ich.org/sites/default/files/Q5E_Guideline.pdf"
    },
    {
      "title": "Gemtuzumab Receives New FDA Approval for Acute Myeloid Leukemia",
      "url": "https://www.cancer.gov/news-events/cancer-currents-blog/2017/gemtuzumab-fda-leukemia"
    },
    {
      "title": "FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast Cancer",
      "url": "https://pubmed.ncbi.nlm.nih.gov/33753456/"
    },
    {
      "title": "La FDA aprueba la primera terapia dirigida para el cáncer de mama bajo en HER2",
      "url": "https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-la-primera-terapia-dirigida-para-el-cancer-de-mama-bajo-en-her2"
    },
    {
      "title": "Tumor Marker Tests in Common Use",
      "url": "https://www.cancer.gov/about-cancer/diagnosis-staging/diagnosis/tumor-markers-list"
    },
    {
      "title": "Breast Cancer Treatment (PDQ®)",
      "url": "https://www.cancer.gov/types/breast/hp/breast-treatment-pdq"
    },
    {
      "title": "ENHERTU prescribing information, 2022",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761139s022lbl.pdf"
    },
    {
      "title": "Ongoing Cancer Accelerated Approvals",
      "url": "https://www.fda.gov/drugs/resources-information-approved-drugs/ongoing-cancer-accelerated-approvals"
    },
    {
      "title": "Potential Mechanisms of Interstitial Lung Disease Induced by Antibody–Drug Conjugates Based on Quantitative Analysis of Drug Distribution",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11791479/"
    },
    {
      "title": "Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer",
      "url": "https://pubmed.ncbi.nlm.nih.gov/34534430/"
    },
    {
      "title": "SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads",
      "url": "https://pubmed.ncbi.nlm.nih.gov/30131388/"
    },
    {
      "title": "Quantitative characterization of in vitro bystander effect of antibody-drug conjugates",
      "url": "https://pubmed.ncbi.nlm.nih.gov/27670282/"
    },
    {
      "title": "Quantitative Characterization of In Vitro Bystander Effect of Antibody-Drug Conjugates",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5112145/"
    },
    {
      "title": "Mylotarg regulatory history and pharmacovigilance review",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000OtherR.pdf"
    },
    {
      "title": "Clinical Review: Mylotarg (gemtuzumab ozogamicin)",
      "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761060Orig1s000Orig1Orig2s000MedR.pdf"
    },
    {
      "title": "Clinical Superiority Findings",
      "url": "https://www.fda.gov/industry/designating-orphan-product-drugs-and-biological-products/clinical-superiority-findings"
    }
  ],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}